Article

The transcriptional coactivator MAML1 regulates p300 autoacetylation and HAT activity

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
Nucleic Acids Research (Impact Factor: 8.81). 04/2009; 37(9):2996-3006. DOI: 10.1093/nar/gkp163
Source: PubMed

ABSTRACT MAML1 is a transcriptional coregulator originally identified as a Notch coactivator. MAML1 is also reported to interact with other coregulator proteins, such as CDK8 and p300, to modulate the activity of Notch. We, and others, previously showed that MAML1 recruits p300 to Notch-regulated genes through direct interactions with the DNA-CSL-Notch complex and p300. MAML1 interacts with the C/H3 domain of p300, and the p300-MAML1 complex specifically acetylates lysines of histone H3 and H4 tails in chromatin in vitro. In this report, we show that MAML1 potentiates p300 autoacetylation and p300 transcriptional activation. MAML1 directly enhances p300 HAT activity, and this coincides with the translocation of MAML1, p300 and acetylated histones to nuclear bodies.

0 Followers
 · 
128 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aberrant activation of Notch signaling has an essential role in colorectal cancer (CRC) progression. Amplified in breast cancer 1 (AIB1), also known as steroid receptor coactivator 3 or NCOA3, is a transcriptional coactivator that promotes cancer cell proliferation and invasiveness. However, AIB1 implication in CRC progression through enhancing Notch signaling is unknown. In this study, we found that several CRC cell lines expressed high levels of AIB1, and knockdown of AIB1 decreased cell proliferation, colony formation and tumorigenesis of these CRC cells. Specifically, knockdown of AIB1 inhibited cell cycle progression at G1 phase by decreasing the mRNA levels of cyclin A2, cyclin B1, cyclin E2 and hairy and enhancer of split (Hes) 1. Furthermore, AIB1 interacted with Notch intracellular domain and Mastermind-like 1 and was recruited to the Hes1 promoter to enhance Notch signaling. Downregulation of AIB1 also decreased CRC cell invasiveness in vitro and lung metastasis in vivo. Besides that, knockout of AIB1 in mice inhibited colon carcinogenesis induced by azoxymethane/dextran sodium sulfate treatment. The mRNA levels of cyclin B1 and Hes5 were downregulated, but p27, ATOH1 and MUC2 were upregulated in the colon tumors from AIB1-deficient mice compared with those from wild-type mice. Thus, our results signify the importance of AIB1 in CRC and demonstrate that AIB1 promotes CRC progression at least in part through enhancing Notch signaling, suggesting that AIB1 is a potential molecular target for CRC treatment.Oncogene advance online publication, 29 September 2014; doi:10.1038/onc.2014.324.
    Oncogene 09/2014; DOI:10.1038/onc.2014.324 · 8.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Three decades of research into p300/CBP, since the first report in 1985, have revealed its importance to normal cell health and etiology of disease. p300/CBP is a key enzyme in higher eukaryotes, where it acts as an effector in myriad major cellular signaling pathways, which modulate protein functions and gene expression in response to a variety of signals. This is accomplished by binding of over 400 protein ligands to its various protein interaction-mediating domains and the acetylation of ∼100 protein substrates. The unusual hit-and-run kinetic mechanism has permitted the identification of p300/CBP-specific acetyltransferase inhibitors, which have shown promising effects in studies in living cells. The protein acetylation and protein binding functions of p300/CBP are intricately interrelated, and both are targets of pharmacological interventions that may have considerable therapeutic applications.
    Chemical Reviews 01/2015; DOI:10.1021/cr500452k · 45.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HDAC inhibitors can regulate gene expression by post-translational modification of histone as well as non-histone proteins. Often studied at single loci, increased histone acetylation is the paradigmatic mechanism of action. However, little is known of the extent of genome-wide changes in cells stimulated by the hydroxamic acids, TSA and SAHA. In this article we map vascular chromatin modifications including histone H3 acetylation of lysine 9 and 14 (H3K9/14ac) using chromatin immunoprecipitation (ChIP) coupled with massive parallel sequencing (ChIP-seq). Since acetylation mediated gene expression is often associated with modification of other lysine residues we also examined H3K4me3 and H3K9me3 as well as changes in CpG methylation (CpG-seq). RNA sequencing indicates the differential expression of approximately 30% of genes, with almost equal numbers being up- and down-regulated. We observed broad deacetylation and gene expression changes conferred by TSA and SAHA mediated by the loss of EP300/CREBBP binding at multiple gene promoters. This study provides an important framework for HDAC inhibitor function in vascular biology and a comprehensive description of genome-wide deacetylation by pharmacological HDAC inhibition.
    Genome Research 04/2014; 24(8). DOI:10.1101/gr.168781.113 · 13.85 Impact Factor